OCGN · NASDAQ
Ocugen, Inc.
$0.77 -0.01 (-1.26%)
Company overview
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on developing gene therapies to cure blindness diseases. The company's pipeline includes OCU400, a novel gene therapy product candidate that restores retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis; OCU410, a gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein in preclinical development for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing, and with Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $261M
- Employees
- 95
- Headquarters
- Malvern, PA
- Website
- ocugen.com
- CEO
- Shankar Musunuri
- Listed
- December 3, 2014
- P/E
- -3.30
- Dividend yield
- 0.00%
Company financials
- Revenue
- $4.5M
- Gross profit
- $4.5M
- Operating income
- -$66.3M
- EBITDA
- -$64.9M
- Net income
- -$71.7M
- EPS
- -$0.23
- Total assets
- $56.9M
- Total debt
- $33.3M
- Gross margin
- 100.00%
- Net margin
- -1,605.22%
- Earnings yield
- -30.26%
OCGN
1D
NASDAQ
O0.77H0.80L0.75C0.78+0.02 (+2.96%)Vol2.41M